Biopharma OS

Built so you never miss the signals that matter

Biopharma OS is engineered to surface insights that fragmented data misses, and deliver complete answers to your most complex questions.

Book a Demo
Agent session

Prompt

Who's got a drug targeting TSLP in trials, and how far did each one get? And where a program died, was that the biology or the business?

Agent using public sources finished · 6 steps

What it found

  1. Tezepelumab, and a shifting list of others.
  2. 11 to 13 drugs named, different every run.
  3. 108 trial results.
  4. 27 are trials of TSLP drugs. 81 are not.
  5. Phases disagree between sources.
  6. Free text. No category to count.
Trials pinned to this target 27
Agent with DrugBank connected finished · 8 steps

What it found

  1. Thymic stromal lymphopoietin. Not the receptor.
  2. 18 drugs. One approved, 17 in trials.
  3. AZD8630 · CM512 · TQC2731 · GB-0895 · WIN378. 17 of 18 are code names.
  4. 131 trials, every NCT identifier.
  5. 120 trials in phases, 11 with no phase.
  6. 29 sponsors. AstraZeneca 43, Amgen 26, Keymed 16.
  7. Verekitug and solrikitug bind the receptor. Excluded.
  8. 4 stopped. One on efficacy. Two were Novartis portfolio calls.
Registered trials, every NCT ID 131
Phase 1 · 35 Phase 2 · 49 Phase 3 · 34 Phase 4 · 2 No phase · 11

The outlines are the 104 trials the public-source agent never reached.

Runs measured Sep 2026

Trusted by industry leading companies

Nippon Shinkyaku
Servier
Bayer
NIH

AI answers you can act on

Get repeatable, sourced answers in minutes by connecting Biopharma OS data, tools, and agents into the systems your teams already use.

  • Sourced and repeatable
  • Grounded in the full landscape
  • Returned in minutes
  • Unbiased and deterministic
One question asked three times. An agent on public sources returns 40, 31 and 12 trials across the three asks, with 21, 20 and 12 sponsors and no stop reasons it can categorise. The same agent with DrugBank connected returns 131 trials, 29 sponsors and 4 typed stop reasons on all three.

Same question. Asked three times.

Who's got a drug targeting TSLP in trials, and how far did each one get? And where a program died, was that the biology or the business?

Agent using public sources 3 answers
Trials found Spon. Stops typedAsk 1 40 21 noneAsk 2 31 20 noneAsk 3 12 12 none
Agent with DrugBank connected 1 answer
Trials found Spon. Stops typedAsk 1 131 29 4Ask 2 131 29 4Ask 3 131 29 4

Runs measured Sep 2026

What you can do

One question, followed all the way down

Start at a target, land on a decision — without leaving the data or the environment you work in.

Connect biology to the competitive landscape

  • One traversal from the KRAS target down through 8 modality classes, 66 drugs, 312 trials and 138 parent companies to 249 indications in trials. ONE TRAVERSAL, SIX JOINS KRAS KRAS P01116 MECHANISM modality classes 8 DRUGS 2 approved, 64 in development 66 TRIALS testing those drugs 312 COMPANIES parents, from 144 sponsors 138 INDICATIONS in trials, against 5 approved 249

    Map the competitive landscape from a target

    Start from a target and explore the drugs that act on it, the trials testing them, and the companies behind that work.

  • Six sponsor strings from the trial records, and 124 more unshown, converging on one Johnson & Johnson parent, then the contrast between 38 trials found by searching the name and 3,769 once subsidiaries are rolled up. SPONSOR STRINGS ON THE TRIAL RECORDS Janssen Research & Dev. J&J Pharmaceutical R&D Actelion Janssen Korea, Ltd. Xian-Janssen Pharma. Johnson & Johnson + 124 more strings Johnson & Johnson ULTIMATE PARENT 41 entities · 130 strings SEARCHING THE NAME trials 38 ROLLED UP trials 3,769

    Know the sponsor behind every trial

    See a competitor's true trial footprint. Trial data traces subsidiaries, rebrands, and acquisitions back to their parent company across 38,000+ normalized sponsor organizations.

  • One approved pembrolizumab indication broken into the fields it is stored as: relationship, disease, line of therapy, required biomarker, combination partners, and population and region. ONE APPROVED INDICATION, AS STRUCTURED DATA Pembrolizumab 1 of 213 statements RELATIONSHIP used in combination to treat DISEASE Primary peritoneal carcinoma LINE OF THERAPY platinum-resistant BIOMARKER REQUIRED PD-L1 GIVEN WITH bevacizumab + paclitaxel POPULATION · REGION adults · US 65 of its 213 indications require a biomarker result. 137 are combination-only.

    See every indication in play

    Pull every indication a drug, target, or mechanism class is being pursued for, then spot where the field is saturated and where the whitespace is.

Go deep on the biology

  • A table comparing half-life, bioavailability, T-max, volume of distribution and clearance across six GLP-1 receptor agonists, with dulaglutide's bioavailability cell opened to show the two dose-specific measurements behind it: 65% at 0.75mg and 47% at 1.50mg, both subcutaneous. GLP-1 RECEPTOR AGONISTS · STRUCTURED PHARMACOLOGY DRUGHALF-LIFEBIOAVAIL.T-MAXVDCLEARANCE Semaglutide168 h89 %56 h8–9.4 L0.039 L/h2 valuesTirzepatide120 h80 %8–72 h9.5 L0.061 L/h2 valuesDulaglutide89.9 h ▼ 65 %24–48 h3.09 L0.142 L/h BEHIND THAT ONE CELL · 2 MEASUREMENTS VALUEDOSEROUTEFORMPOPULATION65 %0.75 mgsubcutaneousinjectionunspecified47 %1.50 mgsubcutaneousinjectionunspecifiedLiraglutide13 h55 %11.7 h13 L1.2 L/hLixisenatide3 h——100 L35 L/hExenatide2.4 h100 %2.1 h28.3 L9.1 L/h

    Compare pharmacology across a class of approved drugs

    Compare exposure, half-life, and peak concentration across a whole drug class. ADME, pharmacodynamics, and pharmacology data is queryable down to the conditions each value was measured under, so it's ready to inform dosing and differentiation.

  • Tamoxifen linked to three proteins: the estrogen receptor is the mechanism, hERG is explicitly not the mechanism, and the androgen receptor is not established. Tamoxifen antagonist Estrogen receptor MECHANISM inhibitor hERG NOT THE MECHANISM antagonist Androgen receptor NOT ESTABLISHED

    Understand the mechanism with causal precision

    See true mechanism of action, free of off-target and metabolic noise. Every target-effect link carries an explicit call — mechanism, not the mechanism, or not established — with the evidence behind it.

  • JAK1 sitting in interferon and interleukin signalling, joined out to atopic dermatitis, alopecia areata and Crohn's disease, and to one class liability: serious infection. Interferon signallingInterleukin signalling JAK1 Atopic dermatitis Alopecia areata Crohn's disease Serious infection

    Trace a mechanism across pathways and diseases

    Follow a target through its pathways and into the diseases it affects. See what's upstream and downstream, and where there might be liabilities.

Work in your environment

  • An alert: three new KRAS trials in the last fourteen days, the newest a Phase 3 from Revolution Medicines, sourced to ClinicalTrials.gov and dated. KRAS last 14 days 3 new trials Phase 3 · Revolution Medicines ClinicalTrials.gov · Aug 20, 2026

    Get alerted when your targets move

    Set a threshold on one drug or a whole target class. Alerts carry their source.

  • DrugBank sitting inside the customer's own environment, joined to their proprietary data with neither side moving. Your environment Your proprietarydata DrugBank

    Bring DrugBank into your environment

    Connect DrugBank to your proprietary data where it already lives. Nothing moves.

  • A saved project on a stack of others, holding a landscape, a monitor and a PK table, shared with three teammates. KRAS competitive review Landscape Monitor PK table RS JL MW

    Save and share your research context

    Save your research context once, then return to it or share it with your team.

One OS, engineered for defensibility

Biopharma OS turns scattered pharma data into sourced, repeatable answers your team can act on, inside the tools you already have.

  1. Access Points

    API and MCPConnects into your agentic workflowWorks with Claude, Copilot, ChatGPT, custom agents WorkspaceThe interface where you assemble, analyze, and
    annotate, manually or through agents.

  2. Applied Intelligence

    Landscape
    analyses     Deterministic
    answers     Monitoring
    alerts     Projects Enriched proprietary
    data
  3. DrugsTargetsTrialsDiseasesMechanisms of actionPathwaysPipelinesCompanies

  4. Knowledge Engine

    Capture and ingest Engineer and structure Validate and review

Applied Intelligence

The intelligence layer biopharma runs on

Biopharma OS's purpose-built agents and tools transform the graph into deterministic, traceable results.

  • Mapping Agent

    Resolves entities against DrugBank data and connects related records.

  • Monitoring Agent

    Tracks drugs, targets, and trials for meaningful updates.

  • Validation Agent

    Verifies source, mechanism, and trial data before delivery.

  • Graph Queries Tool

    Pulls deterministic answers on drugs, targets, and trials.

  • Aggregation and Analytics Tool

    Rolls up trial, target, and sponsor data into trends.

  • Structure and Sequence Search Tool

    Matches compounds by chemical structure or sequence similarity.

  • DDI and Safety Tool

    Surfaces drug interactions and safety signals from trial data.

  • Reproducible Workflows

    Reruns the same analysis with identical steps and results.

Get answers you can trust, every time.

Book a demo